MedicineChemistry

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

C. Hartinger, Stefanie Zorbas-Seifried, M. Jakupec, B. Kynast, H. Zorbas, B. Keppler

2006.5.1JOURNAL OF INORGANIC BIOCHEMISTRY

DOI: 10.1016/j.jinorgbio.2006.02.013

tlooto Summary

The preclinical and early clinical development of KP1019 - from bench to bedside - is recapitulated and promising activity against certain types of tumors is observed.

Abstract

Abstract is not available.

Citation format

HARTINGER, C., et al. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1h-indazole)ruthenate(iii)] (KP1019 or FFC14A). JOURNAL OF INORGANIC BIOCHEMISTRY, 2006, 100 5-6: 891–904.